Surreal illustration of a woman merging with medical imaging scans and a blooming flower, symbolizing breast cancer imaging and hope.

Decoding Breast Cancer Imaging: A Patient's Guide to Understanding Your Options

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 4 min read.

"Navigating the world of mammograms, MRIs, and PET scans can feel overwhelming. This guide breaks down the key imaging technologies used in breast cancer diagnosis, helping you make informed decisions about your health."


Breast cancer remains a significant health concern for women, even with the latest progress in detection and treatment. In 2010, over 200,000 women were diagnosed with breast cancer, and almost 40,000 lost their lives to it. While death rates have fortunately decreased, breast cancer continues to be a leading cause of mortality for women. Early and accurate imaging remains essential for diagnosis and assessment.

Imaging technologies, like mammography, ultrasonography and MRI, are used to diagnose and asses breast cancer's extent. Ongoing upgrades are improving the ability to detect breast tumors. Despite this, imaging advancements have led to increased mastectomy rates and treatment delays. Use of clinical imaging has increased, which has greatly increased healthcare costs.

It's important to understand that the FDA approval pathway for imaging technologies differs from that of new drugs. Imaging manufacturers are not usually required to show the long-term effects of imaging on patient outcomes. Comparative effectiveness research (CER) is a useful way to determine whether imaging methods help to improve patient outcomes.

AI Search Multiple angles on this topic

Accepted Imaging Methods

Breast imaging supports screening, diagnosis, preoperative and treatment assessment, and follow-up. The main modalities are mammography, ultrasound, and magnetic resonance imaging, each with advantages and disadvantages; newer technologies aim to address some of their limitations. Screening may also use digital breast tomosynthesis or contrast-enhanced mammography, while incidental detection can occur through chest CT, abdominal CT or MRI, or PET CT. Full-field digital mammography received FDA approval in January 2000 for the same screening and diagnostic indications as film-based mammography.

Understanding the Key Imaging Technologies for Breast Cancer

Surreal illustration of a woman merging with medical imaging scans and a blooming flower, symbolizing breast cancer imaging and hope.

Several imaging technologies are essential for detecting and staging breast cancer. The milestones of each modality include appearance in peer-reviewed literature, FDA approval, CMS reimbursement, and NCCN guidelines. Let's take a closer look at the common methods:

Mammography is the first imaging test used for women who have positive screening mammograms or signs of breast cancer such as palpable breast lumps, nipple discharge or skin changes. Diagnostic mammography usually includes online review of images and physical examinations. A randomized control trial in 1973, showed a 33% reduction in breast cancer mortality for women screened with mammography and helped this modality achieve widespread clinical acceptance.

  • Full Field Digital Mammography (FFDM): FFDM utilizes digital detectors rather than x-ray film to improve film-based radiology.
  • Mammography CAD: Uses image processing and computer vision to augment a human reader's ability to detect breast lesions.
AI Search Multiple angles on this topic

Evidence and Adoption

The adoption of breast-imaging interventions in the United States has historically been driven largely by reimbursement from government and third-party payers rather than by reported clinical efficacy. FDA approval of a new or modified imaging modality does not necessarily require evidence that it improves patient outcomes. Research on regulatory and reimbursement patterns has also suggested that cost- and resource-effective strategies can improve the likelihood of regulatory approval and speed the path to market. These patterns highlight why regulatory clearance, payment, and demonstrated patient benefit should be considered separately.

Evidence Gaps

Comparative effectiveness research was not used to evaluate breast-imaging technologies before FDA approval, according to the cited review. More recent publications have used comparative effectiveness research to examine diagnostic breast imaging. The review describes this research as a vital component in determining international guidelines. This history means that approval and adoption do not by themselves establish which imaging approach provides the greatest benefit in practice.

Comparing Screening Options

A mammogram is an X-ray image of the breasts and remains the screening technique most people associate with breast cancer detection. It can also be used diagnostically to investigate symptoms or unusual findings on another imaging test, and the breasts are compressed between two firm surfaces during the examination. The listed screening options include mammograms and MRI, while some clinics offer digital mammography with tomosynthesis as a default; the 2D mammogram remains widely accepted and effective in average-risk settings. QT Imaging is described as a proposed non-radiation alternative to mammography in some media reports.

CMS has covered diagnostic mammography since May 1978. Guidelines published by the NCCN have recommended diagnostic mammography for local breast staging for breast cancer since 1996. Other technologies exist, like Ultrasonography, MRI, CT, and PET.

The Future of Breast Cancer Imaging

Diagnostic imaging technologies in breast cancer has made achievements, but long-term effects on breast cancer patients is limited. More study of imaging technologies could reduce recurrence rates, increase survival time and reduce costs. In order to ensure the most effective imaging technologies reach or remain in clinical practice, CER will play a critical role.

AI Search Multiple angles on this topic

A Changing Imaging Landscape

Breast imaging has expanded beyond mammography to include breast ultrasound, breast MRI, contrast-enhanced mammography, tomosynthesis, and molecular breast imaging. A systematic review and meta-analysis can compare the diagnostic value of mammography and ultrasound and provide evidence-based advice for physicians. At the same time, diagnostic errors in mammography, including missed or delayed cancers, remain an important concern, with reader-related cognitive biases and lesion-related factors identified as contributors. The field continues to evolve while addressing both sensitivity and interpretation challenges.

Imaging in Real-World Care

A large prospective study across 12 sites in Germany included 463,094 women and 119 radiologists and evaluated AI-supported screening, which increased breast cancer detection rates by a significant amount according to the reported study summary. Another prospective study across multiple sites in the United States involved 579,583 women and examined a multistage AI-driven workflow for digital breast tomosynthesis mammograms. Separately, a population-based incidence-density case-control study investigated the real-world impact of organized mammography screening on breast cancer mortality among women aged 50 to 74 living in metropolitan areas of Milan, Italy. These studies illustrate how imaging technologies and screening programs are evaluated in large, real-world populations.

What the diagnostic accuracy figures mean

  • 78%For diagnostic mammography in patients with suspicious breast lesions, reported sensitivity ranged from 78% to 93%, while specificity ranged from 87% to 98%. These ranges describe how often the test identified disease and correctly classified those without it in the cited studies; they are not a guarantee for an individual examination.[1]
  • 64.8%A 2006 AHRQ review reported a negative predictive value of 64.8% for PET. In that review, this was considered too low to support routine use of PET to rule out breast cancer after an abnormality was found.[1]

Reading the evidence behind breast imaging

The evidence points to different roles for different tests: mammography and ultrasound have established diagnostic and staging uses, while the cited review describes concerns about PET for ruling out disease and staging. This makes the question not simply whether imaging is used, but what a given method can reliably contribute in a particular context.[1]

What complicates the evidence

  • Comparative effectiveness research was not used to assess these breast-imaging technologies before FDA approval, limiting what the approval history says about patient benefit.[1]

The MRI comparison and its outcome

SettingUnited States[2]
ComparisonMRI versus usual care in a randomized controlled trial[2]
Main outcomeWhether advanced imaging technologies improve patient outcomes and/or decrease costs in real-world settings[2]
Effect sizeNo difference in re-excision rates in a UK randomized controlled trial[2]
Times cited33[2]

What a follow-up would need to show

  • For emerging methods, which differences in long-term outcomes are large enough to distinguish a meaningful patient benefit from increased use alone?[1]
  • How closely do reimbursement and guideline decisions track evidence of clinical benefit when a technology is used in practice?[1]

Questions about the evidence

Why might reimbursement not lead to routine clinical use?

The review gives CT as an example: despite regulatory approval and CMS reimbursement, early studies did not show convincing benefit over other techniques, and few clinicians used it to detect or assess breast lesions locally.[1]

What can ultrasound add in some diagnostic situations?

The review says ultrasound can help distinguish benign cysts from solid masses and can be advantageous when examining dense breast tissue in younger women.[1]

Sources

  1. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines (Europe PMC, 2012)
  2. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines (E-MED LTD, 2012)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1102/1470-7330.2012.0003, Alternate LINK

Title: The Emergence Of Diagnostic Imaging Technologies In Breast Cancer: Discovery, Regulatory Approval, Reimbursement, And Adoption In Clinical Guidelines

Subject: Radiology, Nuclear Medicine and imaging

Journal: Cancer Imaging

Publisher: E-MED LTD

Authors: Laura S. Gold, Gregory Klein, Lauren Carr, Larry Kessler, Sean D. Sullivan

Published: 2012-01-01

Everything You Need To Know

1

What is mammography, and how is it used in breast cancer diagnosis?

Mammography is the first imaging test for women with signs of breast cancer. Full Field Digital Mammography (FFDM) uses digital detectors. Mammography CAD uses image processing to detect breast lesions. Diagnostic mammography is recommended by the NCCN for local breast staging since 1996, and CMS has covered it since May 1978. The randomized control trial in 1973 showed a 33% reduction in breast cancer mortality for women screened with mammography.

2

Which imaging technologies are used to detect breast cancer, and why are they important?

Several imaging technologies are crucial in finding and determining the stage of breast cancer. These technologies, including mammography, ultrasonography, and MRI, are used in the diagnosis and assessment of breast cancer. Ongoing improvements are boosting the capacity to find tumors. It's important to understand the FDA approval pathway for imaging technologies differs from that of new drugs. Imaging manufacturers are not usually required to show the long-term effects of imaging on patient outcomes. Therefore, it is important to focus on the benefits versus risks of the imaging modalities.

3

What are some of the drawbacks associated with advances in breast cancer imaging?

While advancements in breast cancer imaging have led to improvements in detection, they've also contributed to increased mastectomy rates and treatment delays. Additionally, the increased use of clinical imaging has increased healthcare costs. The benefits need to be balanced against the risks and costs involved. These are important considerations when choosing the best imaging method for each patient's needs.

4

How does FDA approval for imaging technologies differ from new drugs, and why is that important?

The FDA approval process for imaging technologies differs from that of new drugs. Imaging manufacturers typically are not required to demonstrate long-term impacts on patient outcomes. This is why Comparative Effectiveness Research (CER) is so important, as it helps to determine whether imaging methods actually improve patient outcomes. CER allows for the critical analysis of different imaging techniques. The insights from CER can help determine if an imaging technology is useful and if it is improving patient outcomes.

5

Why is it important for patients to understand their breast cancer imaging options?

Understanding these imaging options is very important for patients. Mammography is the initial imaging test for women with symptoms. Other important technologies include ultrasonography and MRI. It's essential to be informed about these options so that you can make the right health choices. Consulting with your healthcare team is essential to have all the information you need to make the most informed decision for your situation.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.